BRENTUXIMAB VEDOTIN MAY CUT RADIATION USE IN PEDIATRIC HODGKIN LYMPHOMA

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2021年 / 11卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1318 / 1318
页数：1
相关论文
共 50 条
  • [41] THE COST-EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN HODGKIN LYMPHOMA IN SWEDEN
    Engstrom, A.
    VALUE IN HEALTH, 2014, 17 (07) : A639 - A639
  • [42] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Senter, Peter D.
    Sievers, Eric L.
    NATURE BIOTECHNOLOGY, 2012, 30 (07) : 631 - 637
  • [43] Brentuximab vedotin desensitization in a patient with refractory Hodgkin's lymphoma
    Arora, Anubha
    Bhatt, Vijaya Raj
    Liewer, Susanne
    Armitage, James O.
    Bociek, R. Gregory
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (04) : 361 - 364
  • [44] Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma
    Vinti, Luciana
    Pagliara, Daria
    Buffardi, Salvatore
    Di Ruscio, Valentina
    Stocchi, Francesca
    Mariggio, Elena
    Parasole, Rosanna
    Di Matteo, Antonia
    Petruzziello, Fara
    Paganelli, Valeria
    De Vito, Rita
    Del Bufalo, Francesca
    Strocchio, Luisa
    Locatelli, Franco
    PEDIATRIC BLOOD & CANCER, 2022, 69 (04)
  • [45] Novel immunotherapeutic approaches for pediatric classical Hodgkin lymphoma: Nivolumab or brentuximab vedotin with the AVD regimen
    Okeleji, Olayinka
    Gibson, Amber
    Nunez, Cesar
    Garcia, Miriam B.
    Roth, Michael
    Cuglievan, Branko
    McCall, David
    PEDIATRIC BLOOD & CANCER, 2024, 71 (08)
  • [46] The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Peter D Senter
    Eric L Sievers
    Nature Biotechnology, 2012, 30 : 631 - 637
  • [47] Brentuximab vedotin for the treatment of Hodgkin's and non-Hodgkin's lymphoma
    Reagan, Patrick M.
    Friedberg, Jonathan W.
    EXPERT OPINION ON ORPHAN DRUGS, 2015, 3 (05): : 609 - 618
  • [48] Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma
    Mei, Matthew
    Tsai, Ni-Chun
    Palmer, Joycelynne
    Armenian, Saro
    Chen, Robert
    Rosen, Steven
    Forman, Stephen
    Popplewell, Leslie
    Kwak, Larry
    Martin, Peter
    Maddocks, Kami
    Bond, David
    Herrera, Alex F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (08): : 537 - 542
  • [49] Salvage regimens for Hodgkin's lymphoma in the brentuximab vedotin era
    Vitolo, Umberto
    Chiappella, Annalisa
    LANCET ONCOLOGY, 2018, 19 (02): : 162 - 163
  • [50] Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy
    Moskowitz, Alison J.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2018, : 207 - 212
12345